Search
Nalbuphine
go.drugbank.com/drugs/DB00844ApprovedInvestigationalNalbuphine is the only opioid analgesic that is not a controlled substance in the United States. … It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors.
Synonyms: N-cyclobutylmethyl-4,5α-epoxy-3,6α,14-morphinantriolCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeAnastrozole
go.drugbank.com/drugs/DB01217ApprovedInvestigational[L8863] Anastrozole is also related to [exemestane], a steroidal AI, but its non-steroidal nature provides stark advantages including a lack of steroid-associated adverse effects such as weight gain and … Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to [letrozole], used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer
Clofazimine
go.drugbank.com/drugs/DB00845ApprovedInvestigationalWithdrawn[A203144] Although it carries _in vitro_ activity against other mycobacterium, such as _Mycobacterium tuberculosis_, it is generally considered an ineffective treatment in comparison to classic tuberculosis
Insulin human
go.drugbank.com/drugs/DB00030ApprovedInvestigationalcells that the body is no longer able to produce insulin on its own. … Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin.
Products: Humulin N, Novolin NPioglitazone
go.drugbank.com/drugs/DB01132ApprovedInvestigational[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in vivo_ with little consequence … [L11416] The thiazolidinedione class of medications, which also includes [rosiglitazone] and [troglitazone], exerts its pharmacological effect primarily by promoting insulin sensitivity and the improved
Tralokinumab
go.drugbank.com/drugs/DB12169ApprovedInvestigationalIt neutralizes IL-13 activity by inhibiting its ability to bind with receptors, thus helping to alleviate AD symptoms. … While AD is a heterogenous condition with a variety of apparent genetic and environmental causes,[A242422] it is primarily driven by the pro-inflammatory cytokine interleukin-13 (IL-13).
Terlipressin
go.drugbank.com/drugs/DB02638ApprovedInvestigational[A252672] The drug was first approved by the FDA in September 2022.[L43217] … Compared to endogenous vasopressin, terlipressin has a longer half life and increased selectivity for the V1 receptor.
Levosimendan
go.drugbank.com/drugs/DB00922ApprovedInvestigationalWithdrawnLevosimendan increases calcium sensitivity to myocytes by binding to troponin C in a calcium dependent manner. This increases contractility without raising calcium levels. … It also relaxes vascular smooth muscle by opening adenosine triphosphate sensitive potassium channels. Levosimendan is used to manage acutely decompensated congestive heart failure.
Aluminum hydroxide
go.drugbank.com/drugs/DB06723ApprovedInvestigationalIt is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin.
Mixtures: Neo Tigol Tab, EnoFosphenytoin
go.drugbank.com/drugs/DB01320ApprovedInvestigationalIt works by slowing down impulses in the brain that cause seizures. … Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials.